124 related articles for article (PubMed ID: 30535504)
1. MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.
Jing C; Li H; Du Y; Cao H; Liu S; Wang Z; Ma R; Feng J; Wu J
Mol Med Rep; 2019 Feb; 19(2):1092-1100. PubMed ID: 30535504
[TBL] [Abstract][Full Text] [Related]
2. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
[TBL] [Abstract][Full Text] [Related]
3. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
4. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
Kan G; Wang Z; Sheng C; Chen G; Yao C; Mao Y; Chen S
Adv Sci (Weinh); 2021 May; 8(10):2004344. PubMed ID: 34026451
[TBL] [Abstract][Full Text] [Related]
5. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
7. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
8. EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Spindler KG; Andersen RF; Jensen LH; Ploen J; Jakobsen A
Ann Oncol; 2010 Mar; 21(3):535-539. PubMed ID: 19850635
[TBL] [Abstract][Full Text] [Related]
9. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
Bras-Gonçalves RA; Pocard M; Formento JL; Poirson-Bichat F; De Pinieux G; Pandrea I; Arvelo F; Ronco G; Villa P; Coquelle A; Milano G; Lesuffleur T; Dutrillaux B; Poupon MF
Gastroenterology; 2001 Mar; 120(4):874-88. PubMed ID: 11231942
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
Duran G; Cruz R; Simoes AR; Barros F; Giráldez JM; Bernárdez B; Anido U; Candamio S; López-López R; Carracedo Á; Lamas MJ
J Chemother; 2020 Oct; 32(6):310-322. PubMed ID: 32441565
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
13. The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.
Wei W; Ma XD; Jiang GM; Shi B; Zhong W; Sun CL; Zhao L; Hou YJ; Wang H
Oncol Res; 2020 Sep; 28(4):423-438. PubMed ID: 32331534
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
15. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
16. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
[TBL] [Abstract][Full Text] [Related]
17. Sodium Selenite Enhanced the Anti-proliferative Effect of MEK-ERK Inhibitor in Thyroid Cancer Cells.
Kim JB; Yang EY; Woo J; Kwon H; Lim W; Moon BI
In Vivo; 2020; 34(1):185-190. PubMed ID: 31882478
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study.
Badary DM; Elkabsh MM; Mady HH; Gabr A; Kroosh SS
Appl Immunohistochem Mol Morphol; 2020; 28(10):741-747. PubMed ID: 32118594
[TBL] [Abstract][Full Text] [Related]
19. Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors.
Geest CR; Buitenhuis M; Groot Koerkamp MJ; Holstege FC; Vellenga E; Coffer PJ
Blood; 2009 Oct; 114(16):3402-12. PubMed ID: 19667405
[TBL] [Abstract][Full Text] [Related]
20. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
Smutny T; Bitman M; Urban M; Dubecka M; Vrzal R; Dvorak Z; Pavek P
Arch Toxicol; 2014 Dec; 88(12):2243-59. PubMed ID: 24819614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]